The authors describe a proprietary process for producing a stable, topical interferon alpha-2b formulation that can deliver large drug molecules into the skin or mucosa.
John Docherty
Advertisement
John Docherty, M. Sc., is president and chief operating officer at Helix BioPharma.
Articles by John Docherty
Advertisement
Latest Updated Articles
Stabilization of Interferon alpha-2b in a Topical CreamPublished: July 2nd 2009 | Updated:
Advertisement
Advertisement
